A randomised Phase II study of Enzalutamide (MDV3100) in combination with AZD5363 in Patients with Metastatic Castration - Resistant Prostate Cancer

Trial Profile

A randomised Phase II study of Enzalutamide (MDV3100) in combination with AZD5363 in Patients with Metastatic Castration - Resistant Prostate Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 22 Jun 2017

At a glance

  • Drugs AZD 5363 (Primary) ; Enzalutamide (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms RE-AKT
  • Most Recent Events

    • 18 Jun 2017 Status changed from recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 18 Feb 2017 Results of the phase I run-in (n=16), presented at the 2017 Genitourinary Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top